Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Amcor PLC (AMCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Amcor PLC — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Amcor PLC trades at $41.83 (market cap $20.55B). The key difference: Amcor PLC is far larger — about 4.6× ACADIA Pharmaceuticals Inc.'s market cap, and Amcor PLC pays a 5.85% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AMCR | |
|---|---|---|
Market Cap | $4.49B | $20.55B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $50.58 |
52-Week Low | $20.06 | $36.69 |
Enterprise Value | $3.69B | $35.67B |
Dividend Yield | — | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AMCR trades at $44.45, down 1.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported revenue of $15.01B in 2025, with net income of $511M, and has beaten EPS estimates for the last three quarters. Recent news highlights sustainable packaging partnerships and leadership changes aimed at growth.
The stock offers a moderate upside to the consensus price target of $45.75, supported by a 69% analyst buy rating, but faces risks from integration challenges post-Berry acquisition and a high P/E ratio of 35.84. Earnings growth and synergy realization are key catalysts for 2027 recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →
